ClinicalTrials.gg
RecruitingNCT06856226Updated Nov 9, 2026

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

An observational study in Leukemia, Lymphoma and Hematologic Malignancy, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 9, 2026Study contact changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
88
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Leukemia by National Cancer Institute (NCI) — 5 open to participants now, 7 under way, none of them phase 3. Leukemia · National Cancer Institute (NCI).

Planned enrollment
17th of 23
88 · median 482
Started
2026
with 2 others
Observational
23 of 75
4 open now
Registered
73rd of 75
by date

Among the 75 studies in Leukemia by National Cancer Institute (NCI), this one is the 17th largest by planned enrollment of the 23 observational ones that give a count, is one of 3 that started in 2026, is one of 23 observational ones, and was the 73rd registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.

Browse Leukemia studies →

Open to participants now

5 of the 75 studies in Leukemia by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Leukemia by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient s circulation and tissues.

Post-HSCT recipients may receive a medication in which the dosing needs to be adjusted based on genetic variation.

While genes in donor genome may influence dosing and administration of some agents, the majority of established gene-drug pairs in pharmacogenetics are related to expression of metabolic or transporting enzymes located in recipients tissues, often the liver.

Determining which genetic variants influence drug disposition in HSCT recipients is complicated by chimerism in samples that are routinely collected for determining genotype. However, chimerism in tissues is poorly studied in this patient population.

Objectives:

To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic HSCT.

Eligibility:

People ages 18 years and older who are enrolled on a clinical trial at the NIH Clinical Center under which they will donate or receive an allogeneic HSCT.

Design:

DNA is collected prior to HSCT and for two years after HSCT.

Blood will be collected and skin fibroblast cell lines will be established prior to HSCT to serve as a reference genome.

Blood, buccal cells, skin, and hair will be monitored for the development of mixed chimerism via detection of short tandem repeats. Liver biopsies will be collected from participants undergoing hepatic surgery.

Pharmacoscan arrays will be conducted to determine which samples are useful for pharmacogenetic testing in participants who receive allogeneic HSCT.

A probe drug cocktail will be administered pre- and post-HSCT to determine if transplantation alters the metabolic phenotype of liver enzymes.

...

Read the detailed description

Background:

  • After an allogeneic hematopoietic stem cell transplant (HSCT), the donor genome is found in the recipient fs circulation and tissues.
  • Post-HSCT recipients may receive a medication in which the dosing needs to be adjusted based on genetic variation.
  • While genes in donor genome may influence dosing and administration of some agents, the majority of established gene-drug pairs in pharmacogenetics are related to expression of metabolic or transporting enzymes located in recipients f tissues, often the liver.
  • Determining which genetic variants influence drug disposition in HSCT recipients is complicated by chimerism in samples that are routinely collected for determining genotype. However, chimerism in tissues is poorly studied in this patient population.

Primary Objective:

-To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic HSCT.

Eligibility:

  • Age >=18 years
  • Must be enrolled on a clinical trial at the NIH Clinical Center under which they will donate or receive an allogeneic HSCT

Design:

  • DNA is collected prior to HSCT and for two years after HSCT.
  • Blood will be collected and skin fibroblast cell lines will be established prior to HSCT to serve as a reference genome.
  • Blood, buccal cells, skin, and hair will be monitored for the development of mixed chimerism. Liver biopsies will be collected from participants undergoing hepatic surgery.
  • Whole genome sequencing with Aldy analysis will be conducted to determine which samples are useful for pharmacogenetic testing in participants who receive allogeneic HSCT.
  • A probe drug cocktail will be administered pre- and post-HSCT to determine if transplantation alters the metabolic phenotype of liver enzymes.
  • Up to 88 participants will be enrolled.
03

Conditions studied

  • Leukemia
  • Lymphoma
  • Hematologic Malignancy

Keywords

  • Allogeneic Transplant
  • Hematopoietic Cell Transplant
  • Bone Marrow Transplant
  • peripheral blood transplant
  • Chimerism
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Any gender, any age greater than or equal to 18 years, who will donate or receive an allogeneic HSCT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years
  • Participants must be enrolled on a clinical trial at the NIH Clinical Center (CC) under which they will donate or receive an HSCT. The participant and their donor must enroll together to provide a complete set of samples for analysis.
  • Ability of subject to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  • Donors are not allowed to enroll without a recipient
  • Prior HSCT
  • History of psychiatric disorder which may compromise compliance with protocol requirements.
  • Pregnant and lactating individuals
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
88 participants (estimated)

Groups and cohorts

  • Cohort 1

    Participants undergoing allogeneic HSCT and donors

    Other: Arm 1

Interventions

  • OtherArm 1

    Short tandem repeat (STR) analysis from genomic DNA extracted from biospecimens.

06

What researchers measure

Primary outcomes

  1. To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic hematopoietic stem cell transplant (HSCT)

    Obtaining genotype for analysis of pharmacogene activity by understanding the degree chimerism in commonly utilized diagnostic samples.

    Time frame: Pharmacoscan array will be performed within 1 month pre-BM donation in donors and within 1 month pre-HSCT and 12 months post-HSCT in recipients.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Yes — This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be shared after completion of the primary endpoint per the data management sharing plan.

Access criteria: Data may be requested by contacting the Principal Investigator.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 56 months after the start.

Of 96 non-industry observational studies under Leukemia, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 269. This study's planned 56 months is below that.

Counting every sponsor, half of 110 studies reached it within 119 months; a quarter within 40 and three quarters within 269.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2027 → Dec 2030 and completion Dec 2028 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2025
First posted
Mar 4, 2025
StartActual
Mar 4, 2026
Primary completionEst.
Dec 1, 2030was Dec 2027
CompletionEst.
Dec 1, 2031was Dec 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2027→Dec 1, 2030
Nov 4, 2026
Study completion
Dec 1, 2028→Dec 1, 2031
Nov 4, 2026
Contact
Study contact changed: a•••@nih.gov · •••4889→c•••@mail.nih.gov · •••6009. See the current contact
Nov 9, 2026
Show all 3 updates
  1. Nov 9, 2026
    Contact Study contact changed: a•••@nih.gov · •••4889→c•••@mail.nih.gov · •••6009. See the current contact
    + 1 other change: verification date
  2. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date
  3. Nov 4, 2026
    Primary completion Dec 1, 2027→Dec 1, 2030
    Study completion Dec 1, 2028→Dec 1, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06856226
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 4, 2026
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Ashley E Carpenter
Contact
carpentera@mail.nih.gov
(240) 760-6009
Christopher G Kanakry, M.D.
Contact
christopher.kanakry@nih.gov
(240) 760-6171
Christopher G Kanakry, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion